Cabozantinib
|
- ₹0
- Product name: Cabozantinib
- CAS: 849217-68-1
- MF: C28H24FN3O5
- MW: 501.51
- EINECS:692-846-8
- MDL Number:MFCD20926324
- Synonyms:Cabozantinib(XL184Malate);Cabozantinib (XL184, BMS-907351);XL-186;1,1-cyclopropanedicarboxamide, n'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-;N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide Cabozantinib (XL184, BMS-907351);Cabozantinib, >=98%;1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Cabozantinib
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Melting point :212-215°C
Boiling point :758.1±60.0 °C(Predicted)
Density :1.396
storage temp. :-20°C
solubility :Soluble in DMSO
form :White powder.
pka :13.86±0.70(Predicted)
color :White
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChIKey :ONIQOQHATWINJY-UHFFFAOYSA-N
SMILES :C1(C(NC2=CC=C(OC3C4C(N=CC=3)=CC(OC)=C(OC)C=4)C=C2)=O)(C(NC2=CC=C(F)C=C2)=O)CC1
Boiling point :758.1±60.0 °C(Predicted)
Density :1.396
storage temp. :-20°C
solubility :Soluble in DMSO
form :White powder.
pka :13.86±0.70(Predicted)
color :White
Stability :Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
InChIKey :ONIQOQHATWINJY-UHFFFAOYSA-N
SMILES :C1(C(NC2=CC=C(OC3C4C(N=CC=3)=CC(OC)=C(OC)C=4)C=C2)=O)(C(NC2=CC=C(F)C=C2)=O)CC1
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Danger | |||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||
| Precautionary statements: |
|
Description
XL184 is a pan tyrosine kinase inhibitor that primarily targets VEGFR2 (IC50 = 0.035 nM) and c-Met (IC50 = 1.3 nM) but also inhibits RET, c-Kit, Axl, FLT3, and Tie2 (IC50s = 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively). In in vivo breast, lung, and glioma tumor models that represent dysregulated c-Met and VEGFR signaling, XL184 was shown to reduce tumor and endothelial cell proliferation, inhibiting both angiogenesis and metastasis. XL184 has undergone clinical trial in a broad number of cancers, including thyroid carcinoma, prostate cancer, ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma, and glioblastoma.Related product price
- Crizotinib
₹13174.03 - Sunitinib Malate
₹15891.1-63477.8 - Dacomitinib (PF299804)
₹5000-14200